Skip to Content

  • Search

View Additional Section Content

ECOG E1609 - A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon Alpha-2b for Resected High-Risk Melanoma.

For more information on this trial, click the link below.

https://clinicaltrials.gov/ct2/show/NCT01274338?term=ecog+e1609&rank=1

Clinical Trial Categories

  • Melanoma
Contact
The Rosenfeld Cancer Center at 215-481-2402

Location

  • The Rosenfeld Cancer Center

Find a Physician
Search Our Directory

215-481-MEDI

Schedule a
Test

215-481-EXAM

Clinical Trials Details